Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinSwissMalen = Six groups of five animals; figures state n = 5; toxicity a…Oral gavageResin 1, 10 and 100 mg/kg in the HCl/ethanol model and 10 a…Pre-treatment 50 minutes before HCl/ethanol induction and 30 minutes before ind…
Model: Two acute gastric ulcer models: oral 0.2 mL of 0.3 microM HCl in 60% ethanol with stomachs taken 1 hour later, and indomethacin 40 mg/kg intraperitoneally with stomachs taken 5 hours later, after 24 hours fasting
Oral resin reduced gastric lesions versus vehicle in both models, with lesion indices of 0.89 and 1.65 relative units at 10 and 100 mg/kg versus 31.89 in the HCl/ethanol control, and 1.61 and 1.93 versus 4.72 in the indomethacin control.
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.